Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Safety Reporting IN Clinical Trials
ADVERSE EVENT REPORTING
What is a Data and Safety Monitoring Plan and how do I get one? Presented by Office of Human Research Protection.
UNANTICIPATED PROBLEMS INVOLVING RISKS TO SUBJECTS OR OTHERS & INCIDENTS OF NON-COMPLIANCE ( AKA PROTOCOL DEVIATIONS ) TRACY RIGHTMER, JD, CIP COMPLIANCE.
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
The Institutional Review Board. What is an IRB? An IRB is committee set up by an institution to review, approve, and regulate research conducted under.
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
Capturing and Reporting Adverse Events in Clinical Research
Director, Investigator Support & Integration Services, OCTRI
Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
Human Research Protection Program CHR Post-Approval Event Reporting Wednesday, April 11, 2012 Beth Shields, MA, CIP, CCRA Quality Assurance Coordinator.
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
CUMC IRB Investigator Meeting Human Subjects Research Non-Compliance September 15, 2005.
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
Vanderbilt Human Research Protections Program
Defining Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
AAHRPP Accreditation Karen L. Smarr, PhD Human Research Compliance Officer Truman VA Hospital, Columbia, MO Cincinnati, OH March 19, 2007.
Using the short form and reporting adverse events Erin Coons, Senior IRB Specialist, COMIRB 1.
Reporting Unanticipated Problems and Adverse Events: A Change in Policy Mary A. Banks RN, BS, BSN Director, BUMC IRB Wednesday, November 14, 2007.
Unanticipated Problems Potentially Involving Risks to Subjects or Others Research Protections Office Serving UVM and FAHC Updated April 2012.
New Adverse Event Reporting Policy Effective September 1, 2007.
Office of Research Oversight ORO Reporting Adverse Events in Research to ORO Paula Squire Waterman, MS, CIP Department of Veterans Affairs Office of Research.
Sara Brand Associate Director Research Compliance Administration.
Regulatory criteria for approval Bob Craig, July 2007.
Planned Emergency Research Exception from Informed Consent Requirements September 2007.
Adverse Event/Unanticipated Problems Policy and Procedures November 2007.
Office of Research Oversight 1 VHA Handbook Research Compliance Reporting Requirements Revised May 21, 2010 (Presentation prepared for HRPP 101,
TERRENCE F. ACKERMAN, PH.D. PROFESSOR OF BIOETHICS CHAIR, UTHSC IRB.
Understanding Unanticipated Problems (UPs) Elizabeth Ness, RN, MS Director, Staff Development Office of the Clinical Director Center for Cancer Research,
Human Research Protection Program & IRB Responsibilities Marisue Cody, PhD Director Center on Advice & Compliance Help.
1 Unanticipated problems Melody Lin, Ph.D. December,
Office of Research Oversight 1 VHA Handbook Research Compliance Reporting Requirements HRPP September
Continuing Review Presented by: Karen Jeans, PhD, CCRN, CIP Program Analyst, COACH.
APPROVAL CRITERIA AN IRB INFOSHORT MAY CFR CRITERIA FOR IRB APPROVAL OF RESEARCH In order for an IRB to approve a research study, all.
Office of Research Oversight 1 Office of Research and Development Local Accountability Meeting January 2009.
INVESTIGATOR RESPONSIBILITIES C. Karen Jeans, MSN COACH Project Analyst.
Legal Responsibilities for Studies Conducted or Supported by HHS Michael A. Carome, M.D. Associate Director for Regulatory Affairs Office for Human Research.
Ethical and Regulatory Oversight of Human Subjects Research in the VA C. Karen Jeans, PhD, CCRN, CIP COACH Program Analyst September 29, 2010.
GEORGIA STATE UNIVERSITY IRB ADAPTED FROM DHHS GUIDANCE ON UNANTICIPATED PROBLEMS Unanticipated Problems.
Main Line Hospitals Institutional Review Board Unanticipated Problems Anne Marie Hobson, BSN, JD, ORA Director Theresa Greaves, ORA Manager.
Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Unanticipated Problems 15 th FERCAP International Conference 24 Nov 15 Nagasaki, Japan.
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.
Conditional IRB Approval
Assessing expectedness of an adverse event
What is a Data and Safety Monitoring Plan and how do I get one?
Reportable Events & Other IRB Updates February 2017
Adverse Event Reporting: Trials and Tribulations
Pharmacovigilance in clinical trials
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Investigator Responsibilities in Human Subjects Research
Jeffrey M. Cohen, Ph.D. CIP President HRP Associates, Inc.
Navigating Non-Compliance
SERIOUS ADVERSE EVENTS REPORTING
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Reporting to the CPHS: Unanticipated Problems & Serious Adverse Events
Exploring 45 CFR , Criteria for IRB Approval of Research
Ramy Abdelrahman, MD Division of Pediatric and Maternal Health (DPMH)
HHS Reporting Requirements and Adverse Events
Event Reporting in Human Subjects Research
Policy on Prompt Reporting
Research with Human Subjects
Presentation transcript:

Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst

Objectives Define “adverse event” Describe “unanticipated problems involving risks to subjects to others” Identify examples of adverse events and unanticipated problems involving risks to subjects to others

Why Report Adverse Events and Unanticipated Problems? Because it helps ensure the safety of participants in human subject research, by providing information to the IRB and cognizant oversight agencies, and Because it is required

Regulatory Background Common Rule “Adverse Events” do not exist Unanticipated problems involving risks to subjects or others (38 CFR (a))

Regulatory Background FDA Regulations Adverse Event (21 CFR ) Adverse Experience (21 CFR ) Adverse Effect (21 CFR ) Unanticipated Adverse Device Effect (21 CFR ) Unanticipated Problems involving risks to subjects or others (21 CFR (b))

The Common Rule Requires: “… written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and the Department or Agency head of (i) any unanticipated problems involving risks to subjects or others or any serious or continuing noncompliance … ; and (ii) any suspension or termination of IRB approval. ” Source: 38 CFR (b)(5)

Criteria for IRB Approval (.111) A. Required determinations: 1. Risks to subjects are minimized (i) By using procedures consistent with sound research design… (ii) When appropriate, using procedures already being performed… 2. Risks are reasonable in relation to benefits 3. Selection of subjects is equitable 4. Informed consent will be sought prospectively 5. Informed consent is appropriately documented 6. Research plan makes adequate provisions for safety monitoring 7. There are adequate provisions to protect privacy and confidentiality B. When appropriate, additional protections for Vulnerable Subjects

What Is An Adverse Event (AE)? An AE is any untoward occurrence (physical, psychological, economic, social, or legal) which affects a study subject Includes any abnormal sign, symptom, or disease temporally associated with the subject’s participation in the research An AE does not require (or imply) a causal relationship with the research. Source: Modified from definition of Adverse Events in the 1996 International Conference on Harmonization E-6 Guidelines for Good Clinical Practice in OHRP Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events – January 15, 2007

What Is An Adverse Event (AE) according to VHA requirements? An AE is any untoward physical or psychological occurrence in a human subject participating in research. Can be unfavorable and unintended event Includes any abnormal laboratory finding, symptom, or disease associated with the research or the use of a medical investigational test article. Does not necessarily have to have a causal relationship with the research. Source: VHA Handbook , Paragraph 4(b)

Adverse Event Definitions VHA OHRP Guidance An AE is any untoward physical or psychological occurrence in a human subject participating in research. Can be unfavorable and unintended event Includes any abnormal laboratory finding, symptom, or disease associated with the research or the use of a medical investigational test article. Does not necessarily have to have a causal relationship with the research. An AE is any untoward occurrence (physical, psychological, economic, social, or legal) which affects a study subject Includes any abnormal sign, symptom, or disease temporally associated with the subject’s participation in the research An AE does not require (or imply) a causal relationship with the research.

Types of Adverse Events Unanticipated (unexpected) Local (internal) Non-local (external) Related Not related Serious Not Serious

Types of Adverse Events: Unanticipated Unanticipated (unexpected) Event or problem that is new or greater than previously known in terms of nature, severity, or frequency, given the population described in protocol-related documents and the characteristics of the study population. Source: VHA Handbook , Paragraph 4(bb)

Types of Adverse Events: Local and Non-Local Local (internal) Adverse event occurring at the reporting individual’s own facility Source: VHA Handbook , Paragraph 7(c) Non-local (external) Adverse events occurring by subjects enrolled by investigators at other institutions

Types of Adverse Events: Related Related There is a reasonable possibility based upon the available information that the event or outcome may have been caused by or resulted from participation in the research by the subject.

Types of Adverse Events: Serious FDA Regulations An Adverse Event that Results in death, a life-threatening experience, inpatient hospitalization, a persistent or significant disability or incapacity, or a congenital anomaly or birth defect; or Requires, based on a reasonable medical judgment, a medical or surgical intervention to prevent an outcome described above. Source: Section 761(a)(2) of the Food Drug &Cosmetic Act (21 U.S.C. 379aa-1(a)(2))

Types of Adverse Events: Serious VHA Requirements An Adverse Event in Human Research that Results in death, a life-threatening experience, inpatient hospitalization, prolongation of hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect. Also considered serious when medical, surgical, behavioral, social, or other intervention is needed to prevent such an outcome. Source: VHA Handbook , Paragraph 4(w)

Serious Adverse Event Definitions VA FDA Results in death, a life- threatening experience, inpatient hospitalization, prolongation of hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect. Also considered serious when medical, surgical, behavioral, social, or other intervention is needed to prevent such an outcome. Results in death, a life- threatening experience, inpatient hospitalization, a persistent or significant disability or incapacity, or a congenital anomaly or birth defect; or Requires, based on a reasonable medical judgment, a medical or surgical intervention to prevent an outcome described above.

What is the Difference Between Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others? Adverse Events UPs AE/UPR

Definition: Unanticipated Problem Involving Risks to Subjects or Others Common Rule Undefined FDA Regulations Undefined

Unanticipated Problems Involving Risks to Subjects or Others Any incident, experience, or outcomes that meets all three criteria: 1. Unexpected 2. Related or possibly related to participation in research 3. Suggests that the research places subjects or others at a greater risk of harm than was previously known or recognized May be physical, psychological, economic, or social harm Source: OHRP Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events – January 15, 2007

Unanticipated Problems Involving Risks to Subjects or Others vs. Adverse Events Most Adverse Events are not Unanticipated Problems Involving Risks to Subjects or Others All Unanticipated Problems Involving Risks to Subjects or Others are not Adverse Events All Unanticipated Problems Involving Risks to Subjects or Others Adverse are not Serious

Research-related Events or Problems Which Could Be (Or Could Reveal) Unanticipated Problems Involving Risks to Subjects or Others PI-initiated changes in protocol Study amendments, for example: revision of the Consent Form; revision of inclusion/exclusion criteria; addition/deletion of study procedures; etc. Suspension of enrollment New Information (e.g., DSMB reports, publications, sponsor alerts, etc.)

Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others Study sponsors (if multisite study) make reports to PIs, who, in turn, report them to the IRB. Members of the VA research community are responsible for reporting to the IRB per local IRB Standard Operating Policies and Procedures Local IRB Standard Operating Policies and Procedures can exceed but not be less stringent than federal requirements

Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others The IRB determine when events, incidents, or outcomes are Unanticipated Problems Involving Risks to Subjects or Others and report to Institutional Officials

IRB Actions Require study modification Providing additional information to subjects Modify informed consent process/document Educational plan Assignment of Mentor Require additional monitoring Suspension or termination of IRB approval Other actions as determined by the IRB

Reporting By The IRB And Institutional Officials When the IRB determines that a study-related event is an Unanticipated Problem involving Risk to subjects or others, it must be reported to Institutional Official Institutional Official reports to Oversight Agencies and entities as applicable Office of Research Oversight Office for Human Research Protections U.S. Food and Drug Administration Sponsors Other entities

Summary Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others are not synonymous Policies and procedures must describe when and how adverse events and possible unanticipated problems involving risks to subjects or others are reported to the IRB. The IRB reviews reports and determines which are unanticipated problems involving risks to subjects or others